Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305900 | 0.89 | USP30 (0.55) | USP30DGAT1L3MBTL1PTPN11KMT2A | |
| SCHEMBL2304947 | 0.83 | USP30 (0.56) | USP30DGAT1L3MBTL1PTPN11MEN1 | |
| SCHEMBL2304990 | 0.83 | USP30 (0.56) | USP30DGAT1L3MBTL1PTPN11MEN1 | |
| SCHEMBL2358661 | 0.82 | PANK3 (0.51) | DGAT1L3MBTL1TRPV1MEN1KMT2A | |
| SCHEMBL13328426 | 0.82 | PANK3 (0.51) | DGAT1L3MBTL1TRPV1MEN1KMT2A | |
| SCHEMBL3309583 | 0.82 | USP30 (0.55) | USP30DGAT1L3MBTL1PTPN11LMNA | |
| SCHEMBL2302301 | 0.81 | DGAT1 (0.57) | USP30DGAT1TRPV1PTPN11MEN1 | |
| SCHEMBL2303188 | 0.81 | USP30 (0.53) | USP30DGAT1L3MBTL1TRPV1PTPN11 | |
| SCHEMBL3315908 | 0.81 | DGAT1 (0.57) | USP30DGAT1PTPN11SMN1; SMN2LMNA | |
| SCHEMBL2301633 | 0.80 | USP30 (0.53) | USP30DGAT1L3MBTL1TRPV1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | USP30 2018/4885DGAT1 2/4885L3MBTL1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.